News

Report: PSE sales plummet in Washington, Mo., as Rx-only ordinance is enacted

BY DSN STAFF

WASHINGTON, Mo. In the three months following a local ordinance requiring a prescription for pseudoephedrine, sales of the popular nonprescription decongestant plummeted by more than 92% heading into the cough-cold season, the St. Louis Post-Dispatch reported Monday morning, citing figures collected by local pharmacies in accordance with federal law and shared with the Franklin County Sheriff’s Department.

Local pharmacies sold some 4,400 PSE-containing products April through July, the paper reported, or the three months following the end of last year’s cough-cold season. From July 7, the day the prescription-only law was enacted, through Sept. 30, only 310 PSE-containing products were sold.

Those sales have not been replaced by sales of phenylephrine, the alternative decongestant available over-the-counter, local pharmacists told the St. Louis Dispatch.

Sales are also down in local municipalities, the paper reported. Sales dropped an average of 1.3% at Walmart stores in surrounding towns during the same period. In Union, Mo., a township five miles south of Washington that enacted a similar ordinance Oct. 13, sales were down 0.5%.

Approximately 25 miles to the east in St. Louis county, PSE sales are up some 8%, according to the news story. But there an electronic database tracks all  PSE purchases through the county’s 200-plus pharmacies, which gives local law enforcement the ability to crack down on methamphetamine addicts hoping to illegally convert PSE cold medicines into meth without impeding access to law-abiding citizens.

Local Washington officials pointed to the PSE sales decline as a sign of success, according to the paper, especially following a recent opinion issued by Missouri Attorney General Chris Koster that the local OTC-to-RX switch ordinance is legal.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Hy-Vee celebrates the other white meat

BY Alaric DeArment

WEST DES MOINES, Iowa A lot of people complain about pork barrel spending, but not Midwest supermarket chain Hy-Vee.

October is National Pork Month, and the West Des Moines, Iowa-based Hy-Vee announced Friday that sales of the meat have increased more than 25% over October 2008. The chain said it was on track to increase pork tonnage by more than 30%.

 

“With pork prices the lowest they’ve been in more than a decade, we’ve focused our marketing efforts on promoting pork as a great value for consumers,” Hy-Vee assistant VP meat operations Kenan Judge said in a statement. “Today’s shopper is looking for nutritious, economical meal ideas, and pork perfectly fits the bill.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Patients prefer new diabetes drug Victoza over its competitor, survey finds

BY Alaric DeArment

MONTREAL A new diabetes drug satisfied patients more than its competitor, according to a study funded by the drug’s manufacturer.

According to data on 379 patients who took the Diabetes Treatment Satisfaction Questionnaires, presented Thursday at the 20th World Diabetes Congress and published in medical journal The Lancet, patients taking Novo Nordisk’s drug Victoza (liraglutide) perceived less abnormally low or high blood sugar levels — known respectively as hypoglycemia and hyperglycemia — than those taking Byetta (exenatide), made by Eli Lilly & Co., Amylin Corp. and Alkermes.

Victoza is approved in Europe, but Novo Nordisk is still waiting for approval from the Food and Drug Administration in the United States.

“Liraglutide has shown here in a convincing study that it is associated with less nausea, less perceived hypoglycemia and definitely higher patient satisfaction compared to exenatide,” principal investigator Wolfgang Schmidt said in a statement. “Patient-reported outcomes data is an important extension of the efficacy data. If a patient is satisfied with his or her treatment, then they are much more likely to really stick to the treatment over the long term, which is necessary in Type 2 diabetes.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?